1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco

SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, today announces CEO Jeppe Øvlesen, CSO Thomas Jonassen and CBO Jim Knight participate in the J.P. Morgan Healthcare Conference January 13-16 in San Francisco.

“This is a great opportunity for us to talk to continue our discussions with a wide range of potential partners and investors about the ongoing Phase 2b ADVANCE study in newly diagnosed severe rheumatoid arthritis (RA) patients with the lead compound resomelagon (AP1189),” said CEO Jeppe Øvlesen. “This conference will help us kick start what we expect to be an exciting 2025 within business development.”

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com. 

Attachments
SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco

Datum 2024-12-17, kl 07:00
Källa MFN
Bifogade filer
SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet